A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorHansoh BioMedical R&D Company
About this trial
This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.
Eligibility criteria
Qualifiers
Men or women aged more than or equal to (≥) 18 years.
Participants with pathologically confirmed advanced solid tumors.
At least one measurable lesion in accordance with RECIST 1.1
Fresh or archival tumor tissue available for submission.
Disqualifiers
Inadequate bone marrow reserve or serious organ dysfunction.
Uncontrolled pleural effusion or ascites or pericardial effusion.
Known and untreated, or active central nervous system metastases.
Active autoimmune diseases or active infectious disease
Trial design
Treatments tested in this trial
- HS-20108 Monotherapy
Treatment groups
502 Participants
are divided into 9 treatment groups9
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov